Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Psoriasis HELP
Based on 11,184 articles since 2006
||||

These are the 11184 published articles about Psoriasis that originated from Worldwide during 2006-2015.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Treatment of nail psoriasis: best practice recommendations from the Medical Board of the National Psoriasis Foundation. 2015

Crowley, Jeffrey J / Weinberg, Jeffrey M / Wu, Jashin J / Robertson, Andrew D / Van Voorhees, Abby S / Anonymous4730802. ·Bakersfield Dermatology, Bakersfield, California. · Department of Dermatology, Mt Sinai Health System, New York, New York. · Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, California. · National Psoriasis Foundation, Portland, Oregon. · Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia. · ·JAMA Dermatol · Pubmed #25471223.

ABSTRACT: IMPORTANCE: Nail psoriasis can be difficult to treat and has a significant effect on quality of life. Relatively few controlled trials evaluating treatments for nail psoriasis have been published. There is an unmet need for treatment recommendations to guide therapeutic decisions. OBJECTIVE: To develop treatment recommendations for nail psoriasis from the Medical Board of the National Psoriasis Foundation. EVIDENCE REVIEW: A PubMed search for publications on nail psoriasis treatments was performed from January 1, 1947, through May 11, 2014, without language restrictions. FINDINGS: Treatment recommendations for 4 clinical nail psoriasis scenarios were developed based on the evidence reviewed in this study and expert opinion of the Medical Board of the National Psoriasis Foundation. Treatment of nail psoriasis should balance consideration of the extent of skin disease, psoriatic arthritis, and severity of nail disease with concomitant impairment of quality of life. All patients should be evaluated for onychomycosis because this may complicate psoriatic nail disease. For disease limited to the nails, high-potency topical corticosteroids with or without calcipotriol are initial options. For patients with significant nail disease for whom topical therapy has failed, treatment with adalimumab, etanercept, intralesional corticosteroids, ustekinumab, methotrexate sodium, and acitretin are recommended. For patients with significant skin and nail disease, adalimumab, etanercept, and ustekinumab are strongly recommended, and methotrexate, acitretin, infliximab, and apremilast are recommended. Finally, for a patient with significant nail, skin, and joint disease, adalimumab, etanercept, ustekinumab, infliximab, methotrexate, apremilast, and golimumab are recommended. CONCLUSIONS AND RELEVANCE: Treatment of nail psoriasis poses a clinical challenge. Clinical trial data are limited, and results are reported inconsistently, making comparisons among treatment options difficult. The treatment recommendations from the Medical Board of the National Psoriasis Foundation will help guide treatment decisions for clinicians who are treating patients with nail psoriasis.

2 Guideline Consensus on the use of cyclosporine in dermatological practice. Italian Consensus Conference. 2014

Altomare, G / Ayala, F / Bardazzi, F / Bellia, G / Chimenti, S / Colombo, D / Flori, M L / Girolomoni, G / Micali, G / Parodi, A / Peris, K / Vena, G A / Anonymous2750791. ·IRCCS Galeazzi, University of Milan, Milan, Italy - giampiero.girolomoni@univr.it. · ·G Ital Dermatol Venereol · Pubmed #25213388.

ABSTRACT: Cyclosporine A (CsA) efficacy and safety have been proven in various dermatoses both in adults and in children even as long-term treatment. Over the last 25 years, Italian dermatologists have gathered relevant experience about CsA treatment for psoriasis and atopic dermatitis. This paper has been developed by an Italian Consensus Conference and it is aimed at providing recommendations based on real-world clinical experience in adult patients, consistent with efficacy and safety data arising from the scientific literature. The paper is mainly focused on the analysis of the optimal therapeutic schemes for psoriasis and atopic dermatitis, in terms of doses and treatment duration, according to individual characteristics and to the severity of the disease. Moreover, it overviews ideal management, taking into account pharmacological interactions, influence of comorbidities, and the most common adverse events related to CsA treatment.

3 Guideline Psoriasis: guidance on assessment and referral. 2014

Samarasekera, Eleanor J / Smith, Catherine H / Anonymous3680886 / Anonymous3690886. ·National Clinical Guideline Centre, Royal College of Physicians of London. · ·Clin Med (Lond) · Pubmed #24715130.

ABSTRACT: This concise guideline summarises the key recommendations from the recent National Institute for Health and Care Excellence (NICE) clinical guideline on the assessment and management of psoriasis (CG153) that are relevant to the non-dermatologist. The aim is to highlight important considerations for assessment and referral of people with psoriasis, including identification of relevant comorbid conditions. Psoriasis is a common inflammatory skin condition and, especially when severe, can be associated with increased risk of cardiovascular disease, diabetes and depression. Functional, psychological and social morbidity can also be encountered, and the extent of the disability is frequently underestimated. Importantly, highly effective treatments are available. Appropriate assessment and referral of people with psoriasis therefore has the potential to improve outcomes by correctly identifying the appropriate treatment pathway. Assessment should involve not only disease severity but also the impact on patient well-being and whether the patient has any comorbid conditions, such as psoriatic arthritis, which requires rapid referral to a rheumatologist.

4 Guideline Recommendations for the coordinated management of psoriatic arthritis by rheumatologists and dermatologists: a Delphi study. 2014

Cañete, J D / Daudén, E / Queiro, R / Aguilar, M D / Sánchez-Carazo, J L / Carrascosa, J M / Carretero, G / García-Vivar, M L / Lázaro, P / López-Estebaranz, J L / Montilla, C / Ramírez, J / Rodríguez-Moreno, J / Puig, L. ·Servicio de Reumatología, Hospital Clínic de Barcelona e IDIBAPS, Barcelona, Spain. · Servicio de Dermatología, IIS-Princesa, Hospital Universitario La Princesa, Madrid, Spain. · Servicio de Reumatología, Hospital Universitario Central de Asturias, Oviedo, Spain. · Técnicas Avanzadas de Investigación en Servicios de Salud (TAISS), Madrid, Spain. · Servicio de Dermatología, Hospital General de Valencia, Valencia, Spain. · Servicio de Dermatología, Hospital Universitari Germans Trias y Pujol, Badalona, Barcelona, Spain. · Servicio de Dermatología, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Spain. · Servicio de Reumatología, Hospital Universitario Basurto, Bilbao, Spain. · Servicio de Dermatología, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain. · Servicio de Reumatología, Hospital Universitario de Salamanca, Salamanca, Spain. · Servicio de Reumatología, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain. · Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Electronic address: lpuig@santpau.cat. ·Actas Dermosifiliogr · Pubmed #24657018.

ABSTRACT: Psoriatic arthritis, a chronic inflammatory musculoskeletal disease that is associated with psoriasis, causes joint erosions, accompanied by loss of function and quality-of-life. The clinical presentation is variable, with extreme phenotypes that can mimic rheumatoid arthritis or ankylosing spondylitis. Because psoriasis usually presents before psoriatic arthritis, the dermatologist plays a key role in early detection of the latter. As many treatments used in psoriasis are also used in psoriatic arthritis, treatment recommendations should take into consideration the type and severity of both conditions. This consensus paper presents guidelines for the coordinated management of psoriatic arthritis by rheumatologists and dermatologists. The paper was drafted by a multidisciplinary group (6rheumatologists, 6dermatologists, and 2epidemiologists) using the Delphi method and contains recommendations, tables, and algorithms for the diagnosis, referral, and treatment of patients with psoriatic arthritis.

5 Guideline Recommendations of the French Society for Rheumatology (SFR) on the everyday management of patients with spondyloarthritis. 2014

Wendling, Daniel / Lukas, Cédric / Paccou, Julien / Claudepierre, Pascal / Carton, Laurence / Combe, Bernard / Goupille, Philippe / Guillemin, Francis / Hudry, Christophe / Miceli-Richard, Corinne / Dougados, Maxime / Anonymous4160773. ·Service de rhumatologie, université de Franche-Comté (EA 4266), CHRU de Besançon, boulevard Fleming, 25030 Besançon, France. Electronic address: dwendling@chu-besancon.fr. · Hôpital Lapeyronie, Montpellier, Institut Universitaire de Recherche Clinique (EA2415), 34000 Montpellier, France. · Département de rhumatologie, CHU d'Amiens, 80000 Amiens, France; Inserm U1088, UFR Médecine/Pharmacie, Université de Picardie Jules-Verne, 80000 Amiens, France. · Université Paris Est Créteil, Laboratoire d'Investigation Clinique (LIC) EA4393, 94010 Créteil, France; AP-HP, Hôpital Henri-Mondor, Service de Rhumatologie, 94000 Créteil, France. · Association France Spondylarthrites, 19000 Tulle, France. · Departement de Rhumatologie, CHU Lapeyronie,Université Montpellier 1, 34000 Montpellier, France. · CHRU de Tours, service de rhumatologie, UMR CNRS 7292, Université François-Rabelais de Tours, 37000 Tours, France. · Inserm CIC-EC, CHU de Nancy, Service épidémiologie et évaluation cliniques, 54505 Nancy, France. · Cabinet de Rhumatologie, 75008 Paris, France. · Université Paris-Sud, Hôpitaux Universitaires Paris-Sud, AP-HP, 94270 Le Kremlin-Bicêtre, France. · Paris-Descartes University, Medicine Faculty, AP-HP, Cochin hospital, Rheumatology B Department, 75014 Paris, France. · ·Joint Bone Spine · Pubmed #24412120.

ABSTRACT: OBJECTIVE: To develop practice guidelines for the everyday management of patients with spondyloarthritis (including psoriatic arthritis), by updating previous national and international recommendations, based on a review of recently published data. METHODS: A task force and a multidisciplinary literature review group were established. The task force identified the issues that remained unresolved. Based on existing recommendations and recent publications, the task force developed practice guidelines, which were revised by the literature review group and graded according to AGREE. RESULTS: Practice guidelines for the management of spondyloarthritis are reported. After a review of the general diagnostic principles, 30 practice guidelines are given: 5 on general principles, 4 on the management strategy, 5 on non-pharmacological treatments, 7 on conventional pharmacological treatments, 6 on biotherapies, and 3 on surgical treatments and follow-up. CONCLUSION: The updated practice guidelines reported here constitute a global framework that can guide physicians in the everyday management of spondyloarthritis.

6 Guideline From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis. 2014

Motaparthi, Kiran / Stanisic, Vladimir / Van Voorhees, Abby S / Lebwohl, Mark G / Hsu, Sylvia / Anonymous2060770. ·Department of Dermatology, Baylor College of Medicine, Houston, Texas. · University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania. · Mount Sinai School of Medicine, New York, New York. · Department of Dermatology, Baylor College of Medicine, Houston, Texas. Electronic address: shsu@bcm.edu. · ·J Am Acad Dermatol · Pubmed #24220724.

ABSTRACT: BACKGROUND: No consensus exists regarding the optimal laboratory screening for hepatitis B infection that should be performed before initiating therapy with tumor necrosis factor-alfa inhibitors or other immunosuppressive agents. OBJECTIVE: We sought to give guidelines on which tests to order for hepatitis B screening. METHODS: We review the pathophysiology and serology of hepatitis B infection and provide recommendations for screening for hepatitis B infection in patients with psoriasis before beginning anti-tumor necrosis factor-alfa therapy or other immunosuppressive agents. RESULTS: We propose the standardized use of triple serology testing: hepatitis B surface antigen, hepatitis B surface antibody, and hepatitis B core antibody in combination with liver function tests as screening. LIMITATIONS: Conclusions based on review of available literature is a limitation. CONCLUSIONS: All patients with psoriasis who are candidates for tumor necrosis factor-alfa inhibitor should undergo screening for hepatitis B virus infection using the triple serology: hepatitis B surface antigen, hepatitis B surface antibody, and hepatitis B core antibody. It is advisable that patients, who are candidates for ustekinumab, cyclosporine, or methotrexate undergo the same screening.

7 Guideline Recommendations for the management and treatment of psoriatic arthritis. 2013

Carneiro, Sueli / Azevedo, Valderílio Feijó / Bonfiglioli, Rubens / Ranza, Roberto / Gonçalves, Célio Roberto / Keiserman, Mauro / Meirelles, Eduardo de Souza / Pinheiro, Marcelo de Medeiros / Ximenes, Antonio Carlos / Bernardo, Wanderley / Sampaio-Barros, Percival Degrava / Anonymous1930759. · ·Rev Bras Reumatol · Pubmed #24051907.

ABSTRACT: -- No abstract --

8 Guideline Japanese guidance for use of biologics for psoriasis (the 2013 version). 2013

Ohtsuki, Mamitaro / Terui, Tadashi / Ozawa, Akira / Morita, Akimichi / Sano, Shigetoshi / Takahashi, Hidetoshi / Komine, Mayumi / Etoh, Takafumi / Igarashi, Atsuyuki / Torii, Hideshi / Asahina, Akihiko / Nemoto, Osamu / Nakagawa, Hidemi / Anonymous4940758. ·Department of Dermatology, Jichi Medical University, Shimotsuke. · ·J Dermatol · Pubmed #24033880.

ABSTRACT: The clinical use of adalimumab and infliximab, human anti-tumor necrosis factor (TNF)-α monoclonal antibodies, for psoriasis began in January 2010. In January 2011, ustekinumab, a human anti-interleukin-12/23p40 (IL-12/23p40) monoclonal antibody, was newly approved as the third biologic with an indication for psoriasis. While all of these biologics are expected to exhibit excellent therapeutic effect for psoriasis and to contribute to the improvement of quality of life in patients, these drugs require careful safety measures to prevent adverse drug reactions, such as serious infections. The new guidance, an English version prepared by revising the Japanese Guidance/Safety Manual for Use of Biologics for Psoriasis 2011 (in Japanese), is intended to provide up-to-date, evidence-based recommendations and safety measures on the use of biologics, and describes the optimal use of the three biologics, medical requirements for facilities for using biologics, details of safety measures against reactivation of tuberculosis and hepatitis B virus infection, and recommendable combination therapies with biologics.

9 Guideline Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. 2013

Puig, L / Carrascosa, J M / Carretero, G / de la Cueva, P / Lafuente-Urrez, R F / Belinchón, I / Sánchez-Regaña, M / García-Bustínduy, M / Ribera, M / Alsina, M / Ferrándiz, C / Fonseca, E / García-Patos, V / Herrera, E / López-Estebaranz, J L / Marrón, S E / Moreno, J C / Notario, J / Rivera, R / Rodriguez-Cerdeira, C / Romero, A / Ruiz-Villaverde, R / Taberner, R / Vidal, D / Anonymous4460759. ·Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. Electronic address: lpuig@santpau.cat. · ·Actas Dermosifiliogr · Pubmed #24018211.

ABSTRACT: Biologic therapy is a well-established strategy for managing moderate and severe psoriasis. Nevertheless, the high cost of such therapy, the relatively short span of clinical experience with biologics, and the abundance of literature now available on these agents have made evidence-based and consensus-based clinical guidelines necessary. The ideal goal of psoriasis treatment is to achieve complete or nearly complete clearing of lesions and to maintain it over time. Failing that ideal, the goal would be to reduce involvement to localized lesions that can be controlled with topical therapy. Although current evidence allows us to directly or indirectly compare the efficacy or risk of primary or secondary failure of available biologics based on objective outcomes, clinical trial findings cannot be directly translated to routine practice. As a result, the prescribing physician must tailor the treatment regimen to the individual patient. This update of the clinical practice guidelines issued by the Spanish Academy of Dermatology and Venereology (AEDV) on biologic therapy for psoriasis incorporates information from the most recent publications on this topic.

10 Guideline Guidelines for the use of acitretin in psoriasis. Psoriasis Group of the Spanish Academy of Dermatology and Venereology. 2013

Carretero, G / Ribera, M / Belinchón, I / Carrascosa, J M / Puig, Ll / Ferrandiz, C / Dehesa, L / Vidal, D / Peral, F / Jorquera, E / González-Quesada, A / Muñoz, C / Notario, J / Vanaclocha, F / Moreno, J C / Anonymous1720757. ·Grupo de Psoriasis de la Academia Española de Dermatología y Venereología, Spain. gcarrete@aedv.es · ·Actas Dermosifiliogr · Pubmed #23891453.

ABSTRACT: Phototherapy, classic systemic treatments (methotrexate, acitretin, and ciclosporin), and biologic agents (etanercept, infliximab, adalimumab, and ustekinumab) constitute a broad therapeutic arsenal that increases the likelihood of achieving control of severe and extensive disease in patients with psoriasis. Acitretin continues to be a very valuable tool in both monotherapy, in which it is combined with other systemic treatments (classic or biologic), and in sequential therapy. Thanks to its lack of a direct immunosuppressive effect and its ability to achieve a long-term response, acitretin has an important role in the treatment of psoriasis, although this has not always been acknowledged in relevant treatment guidelines. We present consensus guidelines for the use of acitretin in psoriasis drawn up by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. These guidelines provide a detailed account of acitretin, including pharmacological properties, indications and contraindications, adverse effects, and factors that should be taken into account to enhance the safe use of this drug. They also propose treatment strategies for use in routine clinical practice. The overall aim of these guidelines is to define the criteria for the use and management of acetretin in psoriasis.

11 Guideline The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. 2013

Coates, Laura C / Tillett, William / Chandler, David / Helliwell, Philip S / Korendowych, Eleanor / Kyle, Stuart / McInnes, Iain B / Oliver, Susan / Ormerod, Anthony / Smith, Catherine / Symmons, Deborah / Waldron, Nicola / McHugh, Neil J / Anonymous720759. ·Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, Bath BA1 1RL, UK. neil.mchugh@rnhrd.nhs.uk. · ·Rheumatology (Oxford) · Pubmed #23887065.

ABSTRACT: -- No abstract --

12 Guideline Adherence and patient satisfaction with topical treatment in psoriasis, and the use, and organoleptic properties of such treatments: a Delphi study with an expert panel and members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. 2013

Puig, L / Carrascosa, J M / Belinchón, I / Fernández-Redondo, V / Carretero, G / Ruiz-Carrascosa, J C / Careaga, J M / de la Cueva, P / Gárate, M T / Ribera, M / Anonymous2300752 / Anonymous2310752. ·Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. drlpuig@gmail.com · ·Actas Dermosifiliogr · Pubmed #23395400.

ABSTRACT: BACKGROUND: Topical therapy is key to the successful management of psoriasis, and patient adherence to treatment contributes to its effectiveness in the long-term. OBJECTIVES: To establish consensus on adherence to topical treatment in psoriasis, draw up recommendations on how adherence could be improved, and evaluate the properties of the main vehicles used. METHOD: We designed a questionnaire on adherence to topical treatments in psoriasis and another on the properties of the main vehicles used; the 2 questionnaires were evaluated using the Delphi method by a panel of experts and members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology, respectively. RESULTS: Consensus was reached on the following statements: a) treatment adherence increases the effectiveness of topical treatments in psoriasis; b) to improve adherence, it is necessary to improve communication between patients and health care staff, provide written instructions, and simplify treatment with easy-to-use, pleasant products that are preferably applied only once a day; c) treatment satisfaction increases adherence and tends to improve the health-related quality of life of the patient. Ointment was rated the worst vehicle, while foams and solutions were rated the best. Creams and lipophilic gels were considered to be better than ointment in several respects. CONCLUSION: To improve adherence to topical regimens in psoriasis and the effectiveness of such therapy, we need to give patients more information, simplify treatment regimens, and prescribe easy-to-use products that will ensure satisfaction.

13 Guideline 2011 Portuguese recommendations for the use of biological therapies in patients with psoriatic arthritis. 2012

Machado, Pedro / Bogas, Mónica / Ribeiro, Ana / Costa, José / Neto, Adriano / Sepriano, Alexandre / Raposo, Ana / Cravo, Ana Rita / Vilar, António / Furtado, Carolina / Ambrósio, Catarina / Miguel, Cláudia / Vaz, Cláudia / Catita, Cristina / Nour, Dolores / Araújo, Domingos / Vieira-Sousa, Elsa / Teixeira, Filipa / Brandão, Filipe / Canhão, Helena / Cordeiro, Inês / Gonçalves, Inês / Ferreira, Joana / Fonseca, João Eurico / da Silva, José Alberto Pereira / Romeu, José / Ferreira, Júlia / Costa, Lúcia / Maurício, Luís / Cunha-Miranda, Luís / Parente, Manuela / Coutinho, Margarida / Cruz, Margarida / Oliveira, Margarida / Salvador, Maria João / Santos, Maria José / Pinto, Patrícia / Valente, Paula / Abreu, Pedro / Roque, Raquel / Ramiro, Sofia / Capela, Susana / Las, Vera / Barcelos, Anabela / Anonymous4780721. ·Serviço de Reumatologia, Hospitais da Universidade de Coimbra, Praceta Prof. Mota Pinto, 3000-075 Coimbra, Portugal. pedrommcmachado@gmail.com · ·Acta Reumatol Port · Pubmed #22781512.

ABSTRACT: OBJECTIVE: To develop recommendations for the treatment of psoriatic arthritis (PsA) with biological therapies, endorsed by the Portuguese Society of Rheumatology. METHODS: These treatment recommendations were formulated by Portuguese rheumatologists based on literature evidence and consensus opinion. A draft of the recommendations was first circulated to all Portuguese rheumatologists and their suggestions were incorporated in the draft. At a national meeting the recommendations were discussed and all attending rheumatologists voted on the level of agreement for each recommendation. A second draft was again circulated before publication. RESULTS: A consensus was achieved regarding the initiation, assessment of response and switching biological therapies in patients with PsA. Specific recommendations were developed for several disease domains: peripheral arthritis, axial disease, enthesitis and dactylitis. CONCLUSION: These recommendations may be used for guidance in deciding which patients with PsA should be treated with biological therapies. They cover a rapidly evolving area of therapeutic intervention. As more evidence becomes available and more biological therapies are licensed, these recommendations will have to be updated.

14 Guideline S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. 2012

Nast, Alexander / Boehncke, Wolf-Henning / Mrowietz, Ulrich / Ockenfels, Hans-Michael / Philipp, Sandra / Reich, Kristian / Rosenbach, Thomas / Sammain, Adel / Schlaeger, Martin / Sebastian, Michael / Sterry, Wolfram / Streit, Volker / Augustin, Matthias / Erdmann, Ricardo / Klaus, Joachim / Koza, Joachim / Muller, Siegrid / Orzechowski, Hans-Dieter / Rosumeck, Stefanie / Schmid-Ott, Gerhard / Weberschock, Tobias / Rzany, Berthold / Anonymous6100711 / Anonymous6110711. ·Division of Evidence Based Medicine (dEBM), Klinik für Dermatologie, Venerologie und Allergologie, Charité- Universitätsmedizin Berlin, Germany. · ·J Dtsch Dermatol Ges · Pubmed #22386073.

ABSTRACT: Psoriasis vulgaris is a common and often chronic inflammatory skin disease. The incidence of psoriasis in Western industrialized countries ranges from 1.5% to 2%. Patients afflicted with severe psoriasis vulgaris may experience a significant reduction in quality of life. Despite the large variety of treatment options available, surveys have shown that patients still do not received optimal treatments. To optimize the treatment of psoriasis in Germany, the Deutsche Dermatologi sche Gesellschaft (DDG) and the Berufsverband Deutscher Dermatologen (BVDD) have initiated a project to develop evidence-based guidelines for the management of psoriasis. They were first published in 2006 and updated in 2011. The Guidelines focus on induction therapy in cases of mild, moderate and severe plaque-type psoriasis in adults including systemic therapy, UV therapy and topical therapies. The therapeutic recommendations were developed based on the results of a systematic literature search and were finalized during a consensus meeting using structured consensus methods (nominal group process).

15 Guideline [Integrated approach to comorbidity in patients with psoriasis.Working Group on Psoriasis-associated Comorbidities]. 2012

Daudén, E / Castañeda, S / Suárez, C / García-Campayo, J / Blasco, A J / Aguilar, M D / Ferrándiz, C / Puig, L / Sánchez-Carazo, J L / Anonymous2550711. ·Servicio de Dermatología, IIS-Princesa, Hospital Universitario La Princesa, Madrid, España. · ·Actas Dermosifiliogr · Pubmed #22364603.

ABSTRACT: The relationship between psoriasis and associated diseases has drawn particular interest in recent years. To provide appropriate management of psoriasis from an early stage, it is necessary to include prompt diagnosis of concomitant disease and to prevent and treat any comorbidity found. Such an integrated approach also serves to ensure that the drugs used to treat associated diseases do not interfere with the management of psoriasis, and vice versa. This clinical practice guideline on the management of comorbidity in psoriasis has been drawn up to help dermatologists to achieve an integrated approach to this inflammatory disease. The guide focuses primarily on the diseases most often found in patients with psoriasis, which include psoriatic arthritis, cardiovascular disease, nonalcoholic fatty liver disease, inflammatory bowel disease, lymphoma, skin cancer, anxiety, and depression. Cardiovascular disease is approached through the study of its major risk factors (obesity, diabetes mellitus, hypertension, dyslipidemia, and metabolic syndrome). Other cardiovascular risk factors related to lifestyle, such as smoking and alcohol consumption, are also discussed. The overall aim of this guide is to provide the dermatologist with a precise, easy to-use tool for systematizing the diagnosis of comorbidity in these patients and to facilitate decisions regarding referral and treatment once associated diseases have been found. The specific objectives are as follows: a) to review the most common diseases associated with psoriasis, including the prevalence of each one and its importance to the dermatologist; b) to provide guidelines for the physical examination, diagnostic tests, and clinical criteria on which to base a preliminary diagnosis; c) to establish criteria for the appropriate referral of patients with suspected comorbidity; d) to provide information on how therapies for psoriasis may modify the course of associated diseases, and e) to provide information concerning treatments prescribed for associated diseases that may have an impact on the course of psoriasis. This guide has been written by a working group of guideline methodologists and clinical experts. The selection of the diseases included was based on a systematic review of the literature and a summary of available evidence; information on the prevalence of each comorbidity was also taken from the literature. The recommendations on diagnostic criteria are based on the main clinical practice guidelines for each of the diseases discussed and on the recommendations of the expert advisory group. The information regarding the repercussions of psoriasis treatments on comorbid diseases was obtained from the summary of product characteristics of each drug. The statements concerning the impact on psoriasis of the associated diseases and their treatment are based on the review of the literature.

16 Guideline German S3-guidelines on the treatment of psoriasis vulgaris (short version). 2012

Nast, A / Boehncke, W H / Mrowietz, U / Ockenfels, H M / Philipp, S / Reich, K / Rosenbach, T / Sammain, A / Schlaeger, M / Sebastian, M / Sterry, W / Streit, V / Augustin, M / Erdmann, R / Klaus, J / Koza, J / Müller, S / Orzechowski, H D / Rosumeck, S / Schmid-Ott, G / Weberschock, T / Rzany, B / Anonymous1480711 / Anonymous1490711. ·Division of Evidence Based Medicine, Klinik für Dermatologie, Venerologie und Allergologie, Charité-Universitätsmedizin Berlin, Germany. info@psoriasis-leitlinie.de · ·Arch Dermatol Res · Pubmed #22350179.

ABSTRACT: Psoriasis vulgaris is a common and often chronic inflammatory skin disease. The incidence of psoriasis in Western industrialized countries ranges from 1.5 to 2%. Patients afflicted with severe psoriasis vulgaris may experience a significant reduction in quality of life. Despite the large variety of treatment options available, patient surveys have revealed insufficient satisfaction with the efficacy of available treatments and a high rate of medication non-compliance (Richards et al. in J Am Acad Dermatol 41(4):581-583, 1999). To optimize the treatment of psoriasis in Germany, the Deutsche Dermatologische Gesellschaft (DDG) and the Berufsverband Deutscher Dermatologen (BVDD) have initiated a project to develop evidence-based guidelines for the management of psoriasis first published in 2006 and now updated in 2011. The Guidelines focus on induction therapy in cases of mild, moderate, and severe plaque-type psoriasis in adults. This short version of the guidelines presents the resulting series of therapeutic recommendations, which were based on a systematic literature search and discussed and approved by a team of dermatology experts. In addition to the therapeutic recommendations provided in this short version, the full version of the guidelines includes information on contraindications, adverse events, drug interactions, practicality, and costs, as well as detailed information on how best to apply the treatments described (for full version please see Nast et al. in JDDG Suppl 2:S1-S104, 2011 or http://www.psoriasis-leitlinie.de ).

17 Guideline Consensus guidelines for the management of plaque psoriasis. 2012

Hsu, Sylvia / Papp, Kim Alexander / Lebwohl, Mark G / Bagel, Jerry / Blauvelt, Andrew / Duffin, Kristina Callis / Crowley, Jeffrey / Eichenfield, Lawrence F / Feldman, Steven R / Fiorentino, David F / Gelfand, Joel M / Gottlieb, Alice B / Jacobsen, Carmen / Kalb, Robert E / Kavanaugh, Arthur / Korman, Neil J / Krueger, Gerald G / Michelon, Melissa A / Morison, Warwick / Ritchlin, Christopher T / Stein Gold, Linda / Stone, Stephen P / Strober, Bruce E / Van Voorhees, Abby S / Weiss, Stefan C / Wanat, Karolyn / Bebo, Bruce F / Anonymous2830708. ·Department of Dermatology, Baylor College of Medicine, Houston, TX 77030, USA. shsu@bcm.edu · ·Arch Dermatol · Pubmed #22250239.

ABSTRACT: The Canadian Guidelines for the Management of Plaque Psoriasis were reviewed by the entire National Psoriasis Foundation Medical Board and updated to include newly approved agents such as ustekinumab and to reflect practice patterns in the United States, where the excimer laser is approved for psoriasis treatment. Management of psoriasis in special populations is discussed. In the updated guidelines, we include sections on children, pregnant patients or pregnant partners of patients, nursing mothers, the elderly, patients with hepatitis B or C virus infections, human immunodeficiency virus-infected patients, and patients with malignant neoplasms, as well as sections on tumor necrosis factor blockers, elective surgery, and vaccinations.

18 Guideline European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. 2012

Gossec, L / Smolen, J S / Gaujoux-Viala, C / Ash, Z / Marzo-Ortega, H / van der Heijde, D / FitzGerald, O / Aletaha, D / Balint, P / Boumpas, D / Braun, J / Breedveld, F C / Burmester, G / Cañete, J D / de Wit, M / Dagfinrud, H / de Vlam, K / Dougados, M / Helliwell, P / Kavanaugh, A / Kvien, T K / Landewé, R / Luger, T / Maccarone, M / McGonagle, D / McHugh, N / McInnes, I B / Ritchlin, C / Sieper, J / Tak, P P / Valesini, G / Vencovsky, J / Winthrop, K L / Zink, A / Emery, P / Anonymous310706. ·Paris Descartes University, Paris, France. laure.gossec@cch.aphp.fr · ·Ann Rheum Dis · Pubmed #21953336.

ABSTRACT: BACKGROUND: Psoriatic arthritis (PsA) is a clinically heterogeneous disease. Clear consensual treatment guidance focused on the musculoskeletal manifestations of PsA would be advantageous. The authors present European League Against Rheumatism (EULAR) recommendations for the treatment of PsA with systemic or local (non-topical) symptomatic and disease-modifying antirheumatic drugs (DMARD). METHODS: The recommendations are based on evidence from systematic literature reviews performed for non-steroidal anti-inflammatory drugs (NSAID), glucocorticoids, synthetic DMARD and biological DMARD. This evidence was discussed, summarised and recommendations were formulated by a task force comprising 35 representatives, and providing levels of evidence, strength of recommendations and levels of agreement. RESULTS: Ten recommendations were developed for treatment from NSAID through synthetic DMARD to biological agents, accounting for articular and extra-articular manifestations of PsA. Five overarching principles and a research agenda were defined. CONCLUSION: These recommendations are intended to provide rheumatologists, patients and other stakeholders with a consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes, based on combining evidence and expert opinion. The research agenda informs directions within EULAR and other communities interested in PsA.

19 Guideline Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology. 2011

Salvarani, Carlo / Pipitone, Nicolò / Marchesoni, Antonio / Cantini, Fabrizio / Cauli, Alberto / Lubrano, Ennio / Punzi, Leonardo / Scarpa, Raffaele / Spadaro, Antonio / Matucci-Cerinic, Marco / Olivieri, Ignazio / Anonymous5130696. ·Rheumatology Unit, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy. salvarani.carlo@asmn.re.it · ·Clin Exp Rheumatol · Pubmed #21906425.

ABSTRACT: OBJECTIVES: To update the 2006 Italian Society for Rheumatology recommendations for the use of biologic (TNF-α blocking) agents in the treatment of psoriatic arthritis (PsA). METHODS: A panel of experts performed a literature search and identified the items that required updating on the basis of new published data. A draft of the updated recommendations was circulated to a group of Italian Rheumatologists with a specific expertise in PsA and in therapy with biologic agents, and their suggestions were incorporated in the final version. RESULTS: A consensus was achieved regarding the initiation and the monitoring of anti-TNF-α agents in PsA. Inclusion and exclusion criteria were defined and specific recommendations were made for patients with psoriatic peripheral synovitis, spondylitis, enthesitis, and dactylitis, respectively. We also specified criteria for assessment of response to treatment and for withholding and withdrawal of therapy. CONCLUSIONS: These recommendations may be used for guidance in deciding which patients with PsA should receive biologic therapy. Further updates of these recommendations may be published on the basis of the results of new clinical studies and of data from post-marketing surveillance.

20 Guideline [Consensus statement of the Spanish Society of Rheumatology on the management of biologic therapies in psoriatic arthritis]. 2011

Fernández Sueiro, Jose Luis / Juanola Roura, Xavier / Cañete Crespillo, Juan de Dios / Torre Alonso, Juan Carlos / García de Vicuña, Rosario / Queiro Silva, Rubén / Ariza Ariza, Rafael / Batlle Gualda, Enrique / Loza Santamaría, Estíbaliz / Anonymous4700693. ·Servicio de Reumatología, Hospital Universitario A Coruña, A Coruña, España. · ·Reumatol Clin · Pubmed #21794810.

ABSTRACT: OBJECTIVE: Due to the amount and quality variability regarding the use of biologic therapy (BT) in psoriatic arthritis (PsA) patients, the Spanish Society of Rheumatology (SER) has promoted the generation of recommendations based on the best evidence available. These recommendations should serve as reference to rheumatologists and those involved in the treatment of patients with PsA, who are using, or about to use BT. METHODS: Recommendations were developed following a nominal group methodology and based on systematic reviews. The level of evidence and degree of recommendation was classified according to the model proposed by the Center for Evidence Based Medicine at Oxford. The level of agreement was established through Delphi technique. RESULTS: We have produced recommendations for the use of TB currently available for PsA in our country. These recommendations include disease assessment, treatment objectives, therapeutic scheme and switching. CONCLUSIONS: We present an update on the SER recommendations for the use of BT in patients with PsA.

21 Guideline [Narrowband UV-B, monochromatic excimer laser, and photodynamic therapy in psoriasis: a consensus statement of the Spanish Psoriasis Group]. 2011

Carrascosa, J M / López-Estebaranz, J L / Carretero, G / Daudén, E / Ferrándiz, C / Vidal, D / Belinchón, I / Sánchez-Regaña, M / Puig, L / Anonymous2920684. ·Servicio de Dermatología, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, España. jmcarrascosac@hotmail.com · ·Actas Dermosifiliogr · Pubmed #21310368.

ABSTRACT: Novel treatment strategies and new information concerning the management of moderate to severe psoriasis justify a reassessment of the role of the classic therapies in this setting. This consensus statement evaluates narrowband UV-B therapy, which is currently considered the phototherapy option of choice in psoriasis because of its risk-to-benefit ratio. The role of excimer laser and photodynamic therapies are also discussed. These targeted therapies are still only available in a small number of centers in Spain and are used principally in the treatment of localized and recalcitrant forms of psoriasis. We discuss the efficacy and safety of phototherapy as well as treatment regimens, combination therapy, and clinical considerations relating to the characteristics of the patient or the disease.

22 Guideline Optimizing topical therapies for treating psoriasis: a consensus conference. 2010

Zeichner, Joshua A / Lebwohl, Mark G / Menter, Alan / Bagel, Jerry / Del Rosso, James Q / Elewski, Boni E / Feldman, Steven R / Kircik, Leon H / Koo, John / Gold, Linda Stein / Tanghetti, Emil / Anonymous4350672. ·Mount Sinai Medical Center, New York, New York, USA. · ·Cutis · Pubmed #21049712.

ABSTRACT: In 2010, an expert committee of physicians and researchers in the field of dermatology working together as the Psoriasis Process of Care Consensus Panel developed consensus guidelines for the treatment of psoriasis. As much as possible, the guidelines were evidence based but also included the extensive clinical experience of the dermatologists. Psoriasis is a lifelong disease that requires long-term treatment and 80% of psoriasis patients have mild to moderate disease. Topical therapies play an important role in the treatment of psoriasis, especially in patients with mild to moderate disease. Patients usually start with monotherapy; however, in more severe cases (> 10% body surface area [BSA], severely impaired quality of life [QOL], or recalcitrant psoriatic lesions), multiple treatment modalities may be used as part of combination, sequential, or rotational therapeutic regimens. Main treatment options include topical steroids, systemic therapies, topical vitamin D treatments such as vitamin D3 ointment, retinoids, phototherapy, and biologic therapies. Other topical therapies include the following steroid-sparing agents: coal tar, anthralin, calcineurin inhibitors, keratolytics, and emollients. Therapeutic considerations also should focus on adherence, improving QOL, and promoting a good patient-physician relationship.

23 Guideline [Guidelines on the use of methotrexate in psoriasis]. 2010

Carretero, G / Puig, L / Dehesa, L / Carrascosa, J M / Ribera, M / Sánchez-Regaña, M / Daudén, E / Vidal, D / Alsina, M / Muñoz-Santos, C / López-Estebaranz, J L / Notario, J / Ferrandiz, C / Vanaclocha, F / García-Bustinduy, M / Taberner, R / Belinchón, I / Sánchez-Carazo, J / Moreno, J C / Anonymous2990669. ·Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, España. gcarrete@aedv.es · ·Actas Dermosifiliogr · Pubmed #20858386.

ABSTRACT: Psoriasis, a chronic multifactorial inflammatory disease that develops in genetically predisposed individuals, affects approximately 1.5% of the Spanish population. This disease has a negative impact on patients' quality of life, and long-term therapy is often required to control the symptoms. In addition to the classical systemic treatments (methotrexate, acitretin, cyclosporine, and ultraviolet light), the group of drugs known as biologics (etanercept, infliximab, adalimumab, and ustekinumab) provides the dermatologist with an expanded therapeutic armamentarium, thereby improving the likelihood of controlling psoriasis in patients with severe and/or extensive disease. Methotrexate, a classic antipsoriatic drug, is still very useful either as single-drug therapy or in combination with other systemic drugs, particularly as a rescue therapy or combined with biologics. This article aims to establish the role of methotrexate in the treatment of psoriasis. We considered it of interest to develop guidelines for using methotrexate in the management of psoriasis with a view to ensuring the safe and proper use of this drug in the management of psoriasis. This document was developed by consensus among members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology.

24 Guideline Guideline on the management of psoriasis in South Africa. 2010

Raboobee, N / Aboobaker, J / Jordaan, H F / Sinclair, W / Smith, J M / Todd, G / Weiss, R / Whitaker, D / Anonymous3790665. ·raboobee@iafrica.com · ·S Afr Med J · Pubmed #20666218.

ABSTRACT: OBJECTIVE: These guidelines for the management of psoriasis have been developed in an attempt to improve the outcomes of treatment of this condition in South Africa. Psoriasis has a major impact on the quality of life of sufferers, and it is expected that these guidelines, if implemented, will play a role in achieving improved outcome. SCOPE: These guidelines were developed to address the diagnosis and treatment of psoriasis, of differing degrees of severity and in patients of all ages, by all health care professionals involved with its management. RECOMMENDATIONS: All health care workers involved in the management of psoriasis should take note of these guidelines and try to implement them in clinical practice as far as possible. All treatment methods and procedures not substantiated by evidence from the literature should be discontinued and avoided to decrease the financial burden of psoriasis treatment. VALIDATION: These guidelines were developed through general consensus by a group of 8 South African dermatologists (the 'Working Group') sanctioned by the Dermatological Society of South Africa (DSSA), by adaptation for the South African situation of the current guidelines used in the USA, the UK, Germany, Canada and Finland. Draft documents were made available for comment to the dermatological community as a whole via the official website of the DSSA, and the guidelines were presented and discussed at the annual congress of the DSSA in 2008. All input from these sources, where appropriate, were then incorporated into these guidelines. GUIDELINES SPONSOR: Schering-Plough initiated the project and sponsored the meetings of the working group and all costs generated by these meetings. PLANS FOR GUIDELINE REVISION: The field of biologicals and cytokine modulators is in a rapid phase of development, and revision of the scope and content of these guidelines will be ongoing as longer-term data emerge.

25 Guideline British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology. 2010

Ormerod, A D / Campalani, E / Goodfield, M J D / Anonymous810659. ·Department of Dermatology, University of Aberdeen, Foresterhill, Aberdeen AB9 2ZB, UK. a.d.ormerod@abdn.ac.uk · ·Br J Dermatol · Pubmed #20423353.

ABSTRACT: -- No abstract --

Next